REFERENCES
- CAPLEN, N. J., ALTON, E. W. F. W., MIDDLETON, P. G., DORIN, J. R., STEVENSON, B. J., GAO, X., DURHAM, S. R., JEFFERY, P. K., HODSON, M. E., COUTELLE, C., HUANG, L., PORTEOUS, D. J., WILLIAMSON, R., and GEDDES, D. M., 1995, Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nature Medicine, 1, 39–46.
- EPAND, R. M., EPAND, R. F., ORLOWSKI, R. C., SCHLUETER, R. J., BONI, L. T., and Hui, S. W., 1983, Amphipathic helix and its relationship to the interaction of calcitonin with phospholipids. Biochemistry, 22, 5074–5084.
- FINKELSTEIN, M. C., and WEISSMANN, G., 1981, Targetting of liposomes. In Liposomes: From physical structure to therapeutic applications, edited by C. G. Knight (Amsterdam: Elsevier), pp. 443–464.
- ILLum, L., and FISHER, A. N., 1997, Intranasal delivery of peptides and proteins. In Inhalation delivery of therapeutic peptides and proteins, edited by A. L. Adjei and P. K. Gupta (New York: Marcel Dekker), pp. 135–184.
- KAGATANI, S., SHINODA, T., Fukui, M., OHMURA, T., HASUMI, S., and SONOBE, T., 1996, Enhancement of nasal salmon calcitonin absorption by lauroylcarnitine chloride in rats. Pharmaceutical Research, 13, 739–743.
- LAW, S. L., and HUNG, H. Y., 1998, Properties of acyclovir-containing liposomes for potential ocular delivery. International Journal of Pharmaceutics, 161, 253–259.
- LEE, H. I., POLLACK, S., Hsu, S. H., and MrKstc, J. R., 1991, Influence of the mobile phase on salmon calcitonin analysis by reversed-phase liquid chromatography. Journal of Chromatography Science, 29, 136–140.
- LEE, K. C., LEE, Y. J., SONG, H. M., CHUN, C. J., and DELUCA, P. P., 192, Degradation of synthetic salmon calcitonin in aqueous solution. Pharmaceutical Research, 9, 1521-1523.
- LEE, W. A., ENNIS, R. D., LONGENECKER, J. P., and BENGTSSON, P., 1994, The bioavailability of intranasal salmon calcitonin in healthy volunteers with and without a permeation enhancer. Pharmaceutical Research, 11, 747–750.
- LIAN, T., and Ho, R. J., 1997, Cholera toxin B-mediated targeting of lipid vesicles containing ganglioside GN1 to mucosal epithelial cells. Pharmaceutical Research, 14, 1309–1315.
- MAIER, R., BRUGGER, M., BRUCKNER, H., KANB3ER, B., RINIKER, B., and RITTEL, W., 1977, Analogues of human calcitonin V. Influence of basic amino acids in positions 11,17 and 24 on hypocalcaemic activity in the rat. Acta Endocrinologica, 85, 102–108.
- MIATANI, Y., ASANO, S., TAKAHASHI, S., NAKAGAKI, M., and NAGAI, T., 1992, Permeabilty of insulin entrapped in liposome through the nasal mucosa of rabbits. Chemical & Pharmaceutical Bulletin, 40, 1569–1572.
- PrLoN, M., JoRot, W., DE KRUIJFF, B., and DEMEL, R. A., 1987, Interaction of mitochondrial precursor protein apocytochrome c with phosphatidylserine in model membranes. A monolayer study. Biochimica et Biophysica Acta, 902, 207–216.
- RAMJEESINGH, M., HUAN, L. J., WILSCHANSKI, M., DURIE, P., Li, C., GYOMNOREY, K., WANG, Y., KENT, G., TANSWELL, K. A., CUTZ, E., ACKERLY, C., and BEAR, C. E., 1998, Assessment of the efficacy of in vivo CFTR protein replacement therapy in CF mice. Human Gene Therapy, 9, 521–528.
- SLIVERMAN, S. L., 1997, Nasal calcitonin. Endocrine, 6, 199–202.
- SORSCHER, E. J., LOGAN, J. J., FRIZZELL, R. A., LYRENE, R. K., BEBOK, Z., DONG, J. Y., DUVALL, M. D., FELGNER, P. L., MATALON, S., WALKER, L., and WIATRAK, B. J., 1994, Gene therapy for cystic fibrosis using cationic liposome mediated gene transfer: a phase I trial of safety and efficacy in the nasal airway. Human Gene Therapy, 5, 1259–1277.
- WINDISCH, V., DELUCCIA, F., DUHAU, L., HERMAN, F., MENCEL, J. J., TANG, S. Y., and VUILHORGNE, M., 1997, Degradation pathways of salmon calcitonin in aqueous solution. Journal of Pharmaceutical Science, 86, 359–364.